A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in I Mab stock. As of the latest transaction made, Citadel Advisors LLC holds 56,400 shares of IMAB stock, worth $50,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,400
Previous 3,000 1780.0%
Holding current value
$50,760
Previous $5,000 1280.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.03 - $1.72 $61,471 - $102,651
59,681 Added 154.18%
98,389 $122,000
Q2 2024

Aug 14, 2024

BUY
$1.58 - $1.9 $61,158 - $73,545
38,708 New
38,708 $64,000
Q4 2023

Feb 14, 2024

BUY
$1.21 - $1.9 $89,575 - $140,655
74,029 New
74,029 $140,000
Q2 2023

Aug 14, 2023

SELL
$2.95 - $3.85 $323,974 - $422,814
-109,822 Reduced 99.56%
485 $1,000
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $247,404 - $593,609
-80,326 Reduced 42.14%
110,307 $381,000
Q4 2022

Feb 14, 2023

SELL
$3.22 - $4.86 $1.41 Million - $2.12 Million
-437,074 Reduced 69.63%
190,633 $796,000
Q3 2022

Nov 14, 2022

BUY
$4.01 - $12.34 $2.42 Million - $7.44 Million
602,966 Added 2437.11%
627,707 $2.52 Million
Q2 2022

Aug 15, 2022

SELL
$8.27 - $18.43 $36,297 - $80,889
-4,389 Reduced 15.07%
24,741 $280,000
Q4 2021

Feb 14, 2022

SELL
$45.28 - $74.5 $910,852 - $1.5 Million
-20,116 Reduced 40.85%
29,130 $1.38 Million
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $2.29 Million - $3.38 Million
40,018 Added 433.66%
49,246 $3.57 Million
Q2 2021

Aug 16, 2021

BUY
$47.86 - $83.95 $195,460 - $342,851
4,084 Added 79.39%
9,228 $774,000
Q1 2021

May 17, 2021

SELL
$44.38 - $63.97 $3.19 Million - $4.6 Million
-71,847 Reduced 93.32%
5,144 $249,000
Q4 2020

Feb 16, 2021

BUY
$32.94 - $47.15 $2.54 Million - $3.63 Million
76,991 New
76,991 $3.63 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.